Case ReportClinical Studies

Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin

DANIEL KERR, DAMIAN LABER, NATHAN VISWESHWAR and MICHAEL JAGLAL
Anticancer Research March 2018, 38 (3) 1711-1713;

Article Information

vol. 38 no. 3 1711-1713
PubMed 
29491106
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received November 24, 2017
  • Revision received January 2, 2018
  • Accepted January 4, 2018
  • Published online February 28, 2018.
Copyright & Usage 
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. DANIEL KERR1,
  2. DAMIAN LABER1,2,
  3. NATHAN VISWESHWAR1 and
  4. MICHAEL JAGLAL1,2⇑
  1. 1Department of Hematology, Morsani School of Medicine, University of South Florida, Tampa, FL, U.S.A.
  2. 2Section of Satellite Oncology, Moffitt Cancer Center and Division of Hematology/Oncology, Tampa, FL, U.S.A.
  1. Correspondence to: Michael Jaglal, MD, MS, 3 Tampa General Circle, Tampa, FL 33606, U.S.A. Tel: +1 8138448712, Fax +1 8138448115, e-mail mikejaglal{at}yahoo.com
View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin
DANIEL KERR, DAMIAN LABER, NATHAN VISWESHWAR, MICHAEL JAGLAL
Anticancer Research Mar 2018, 38 (3) 1711-1713;
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords